Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FDA Oncology Therapeutics Office Will Contain Three Divisions

Executive Summary

FDA's proposed oncology therapeutics office will be organized into three divisions, Center for Drug Evaluation & Research Medical Policy Director Robert Temple, MD, said June 17 during a Drug Information Association meeting in Washington, D.C

You may also be interested in...



FDA Biologics Center Performance To Be Reviewed By Advisory Committees

The Center for Biologics Evaluation & Research will use its advisory committees to perform an external review of its operations

FDA Biologics Center Performance To Be Reviewed By Advisory Committees

The Center for Biologics Evaluation & Research will use its advisory committees to perform an external review of its operations

FDA Oncology Therapeutics Office Planned; Drug, Biologics Units Will Merge

FDA is understood to be finalizing a plan for a new office of cancer therapeutics that would merge the current drug and biologics review groups within the Center for Drug Evaluation & Research's Office of New Drugs

UsernamePublicRestriction

Register

OM007836

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel